Cas No.: 945245-76-1
PRODUCT INFORMATION
Description
LSD is a peptide-based agent demonstrating selective targeting specificity toward melanoma-derived lymphatic endothelial cells (LECs) in C8161 models, without cross-reactivity to normal tissue lymphatics. Conjugation with pro-apoptotic peptides has been used to study the reduction of tumor lymphatic density in vivo. This peptide serves as a specialized tool for investigating lymphatic-specific molecular interactions and pathways in oncological research models.
Molecular Weight
1009.20
Purity
> 95%
Formula
C₃₉H₇₂N₁₄O₁₃S₂
Product Type
Targeting Peptide
Sequence
Cys-Leu-Ser-Asp-Gly-Lys-Arg-Lys-Cys
Form (20 deg.C)
Solid
Storage Condition
Store sealed at -20°C, away from moisture.
For Research Use Only | Not For Clinical Use
Related products
- HER2-targeted Peptide H6F (CAT#: OLY-1025-YS-5)
- Thrombospondin-1 (1016-1021) (human, Bovine, Mouse) Targeting Peptide (CAT#: OLY-1025-YS-45)
- Breast Cancer Targeting Peptide 18-4 (CAT#: OLY-1025-YS-23)
- MH42 Targeting Peptide (CAT#: OLY-1025-YS-31)
- IETP2 Targeting Peptide (CAT#: OLY-1025-YS-30)
- Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA Targeting Peptide (CAT#: OLY-1025-YS-68)
- CSTSMLKAC (disulfide) Targeting Peptide (CAT#: OLY-1025-YS-55)
- Cyclo(RGDyK) Targeting Peptide (CAT#: OLY-1025-YS-52)
Online Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.